SenzaGen invites to a Live Session at the Facebook group “Aktier – Småbolagsjakten”

SenzaGen will host a live Question and Answer session with the management of the company May 16 between 19:00 – 20:00 CET “Aktier – Småbolagsjakten” is the largest Facebook group in the Nordic region, focusing on publicly traded small companies. The group has over 35 000 members. During the Live Session all questions and answers will […]

SenzaGen will host a live Question and Answer session with the management of the company May 16 between 19:00 – 20:00 CET

“Aktier – Småbolagsjakten” is the largest Facebook group in the Nordic region, focusing on publicly traded small companies. The group has over 35 000 members.

During the Live Session all questions and answers will be in English. Participants will have the opportunity to ask questions directly to company management including Chairman Carl Borrebaeck and CEO Anki Malmborg Hager.

To participate in the session, you must first become a member of the Facebook group “Aktier – Småbolagsjakten”. It is recommended that you submit a membership request at least one day in advance of the presentation to ensure you can participate in the event.

 

To join the group:

  1. Go to https://www.facebook.com/groups/smabolagsjakten
  2. Click the green “+ Join Group” button
  3. You will receive a notification on Facebook when your application to the group is accepted

 

For more information, please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

 

About GARD™
GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have over 90 percent reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75 percent. SenzaGen’s tests are also capable of measuring the potency of a substance’s allergenic properties. Consequently, GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.

About SenzaGen
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com

 

SenzaGen AB are listed on Nasdaq First North in Stockholm and FNCA is the company’s Certified Adviser. For more information, please visit www.senzagen.com